Hutchmed announced that it has completed patient enrollment of ESLIM-01, a pivotal Phase III clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia, or ITP, in China. The last patient was enrolled on December 31.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCM:
- HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
- Hutchmed initiates filing of rolling submission of fruquintinib NDA
- HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
- HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
- HUTCHMED Rises on Positive Results in Gastric Cancer Trial